RecruitingNCT05955014
Data Collection Protocol for Patients With Von Hippel Lindau Disease
Sponsor
M.D. Anderson Cancer Center
Enrollment
125 participants
Start Date
Aug 24, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with von hippel-lindau disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05955014
Related Trials
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT0492407584 locations
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT0740516449 locations
Familial Investigations of Childhood Cancer Predisposition
NCT030502681 location
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NCT075572251 location
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
NCT040741351 location